Tilt Biotherapeutics

TILT Biotherapeutics Ltd is a preclinical stage company working in the field of cancer immunotherapy. TILT aims to translate its unique approach into clinical trials. The company’s patented technology involves utilization of oncolytic viruses for enhancement of tumor T-cell therapy. Initial embodiments of the technology will be used to enhance tumor infiltrating lymphocyte (TIL), chimeric antigen receptor (CAR) and checkpoint inhibiting antibody therapy. The TILT approach has the potential to achieve similar results in CAR therapy of  solid tumors as currently achieved for CD19+ hematological tumors.

Company growth
Type
Private
Founded
2013
Size (employees)
9 (est)+13%
Tilt Biotherapeutics was founded in 2013

Tilt Biotherapeutics Metrics

Tilt Biotherapeutics Summary

Founding Date

2013

Total Funding

$10.6 M

Latest funding size

$10.6 M

Time since last funding

2 months
We estimate that Tilt Biotherapeutics's latest funding round in December 2016 was $10.6 M. In total, Tilt Biotherapeutics has raised $10.6 M

Tilt Biotherapeutics Online Presence

Tilt Biotherapeutics Company Life

You may also be interested in